360 CLINIC, INC. - Laserfiche WebLink

Home Browse Search

during the Term of the Agreement. SUBRECIPIENT agrees to administer the invoicing for said Program as outlined in Exhibit B, and within the terms of this Agreement. (1) Funds for COVID-19 Testing. The compensation required pursuant to this Agreement may be paid by CITY to SUBRECIPIENT from multiple federal, state, and local funding sources (each individually a "Funding Source" and cumulatively the "Funding Sources"), including, but not limited to, CDBG-CV funds and the CITY general fund. If necessary, SUBRECIPIENT will be required to enter into a separate funding agreement for each Funding Source. SUBRECIPIENT will be required to comply with all requirements of each Funding Source, as detailed in the separate funding agreements. The total amount of compensation in said funding agreements shall count toward the total amount due and owing from CITY to SUBRECIPIENT under this Agreement, not compensation in addition to the total amount of this Agreement. If SUBRECIPIENT does not execute any of the separate funding agreements, SUBRECIPIENT will forfeit that amount of funding from that Funding Source, and CITY will have the option to terminate this Agreement. Additionally, in the event any Funding Source is reduced, CITY will have the option to terminate this Agreement. D. Payment of Funds. Said Program Funds shall be paid by CITY to SUBRECIPIENT pursuant to the terms found in Exhibits A and B. SUBRECIPIENT shall submit a daily report to the CITY of the number of tests conducted and a weekly summary to the CITY of tests conducted and positive results received for the week and cumulatively for each site. SUBRECIPIENT shall be obligated to perform such duties as would normally extend beyond the term, including, but not limited to, obligations with respect to indemnification, audits, reporting, data retention/reporting, and accounting. Failure to provide any of the required documentation and reporting will cause CITY to withhold all or a portion of a request for Program Funds, or return the entire invoice to SUBRECIPIENT, until such documentation and reporting has been received and approved by CITY. (1) Third Party Billing and Cost Recovery. SUBRECIPIENT shall be required to seek payment of costs for all COVID-19 tests administered from any available third party sources, including, but not limited to, insurance carriers and other medical providers, prior to applying said services to the Advance Funds from the CITY. If SUBRECIPIENT has not recovered costs from a third party, or received notice of determination of request for costs from a third party, after ninety (90) days, then SUBRECIPIENT may apply said services to the Advance Funds from the CITY. If SUBRECIPIENT receives cost recovery for any COVID-19 test from a third party after applying payment from CITY for said COVID-19 test, SUBRECIPIENT shall return and reimburse such finds to the CITY. (2) Reduction in Program Funding. The CITY reserves the right to reduce the amount of Program Funds to SUBRECIPIENT, or to completely terminate this Agreement, in the CITY's sole discretion, if there is a reduction in CDBG-CV Funds, or any other Funding Source, provided to the CITY, provided that the CITY will pay SUBRECIPIENT for all COVID-19 tests actually distributed or performed prior to SUBRECIPIENT receiving notice from the CITY of any reduction in CDBG-CV Funds, or any other Funding Source, or termination of this Agreement. 3